Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Periodontitis Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Periodontitis Overview | 9 | 1 |
| Pipeline Products for Periodontitis Comparative Analysis | 10 | 1 |
| Periodontitis Therapeutics under Development by Companies | 11 | 1 |
| Periodontitis Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Periodontitis Pipeline Products Glance | 13 | 4 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Periodontitis Products under Development by Companies | 17 | 1 |
| Periodontitis Products under Investigation by Universities/Institutes | 18 | 1 |
| Periodontitis Companies Involved in Therapeutics Development | 19 | 8 |
| Amyndas Pharmaceuticals LLC | 19 | 1 |
| C3 Jian, Inc | 20 | 1 |
| CSL Limited | 21 | 1 |
| Ensol Biosciences Inc. | 22 | 1 |
| Enzo Biochem, Inc. | 23 | 1 |
| Geistlich Pharma AG | 24 | 1 |
| Kaken Pharmaceutical Co., Ltd. | 25 | 1 |
| TGV-Laboratories | 26 | 1 |
| Periodontitis Therapeutics Assessment | 27 | 9 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 17 |
| AMY-101 Drug Profile | 36 | 2 |
| Drug to Antagonize C5aR for Periodontitis Drug Profile | 38 | 1 |
| Enzo-D58 Drug Profile | 39 | 1 |
| GM-0111 Drug Profile | 40 | 1 |
| Hesed-3000 Drug Profile | 41 | 1 |
| Mul-1867 Drug Profile | 42 | 1 |
| PODCRC-OHS Drug Profile | 43 | 1 |
| R-10001 Drug Profile | 44 | 1 |
| Recombinant Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis Drug Profile | 45 | 1 |
| Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders Drug Profile | 46 | 1 |
| Small Molecules for Periodontitis Drug Profile | 47 | 1 |
| ST-266 Drug Profile | 48 | 2 |
| Synthetic Peptides for Periodontitis Drug Profile | 50 | 1 |
| taurolidine Drug Profile | 51 | 1 |
| trafermin Drug Profile | 52 | 1 |
| Periodontitis Dormant Projects | 53 | 1 |
| Periodontitis Discontinued Products | 54 | 1 |
| Periodontitis Product Development Milestones | 55 | 4 |
| Featured News &Press Releases | 55 | 1 |
| Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis | 55 | 1 |
| Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis | 55 | 2 |
| Oct 01, 2015: Kaken Submits a New Drug Application for KCB-1D , Medicinal Product for Periodontal Regeneration | 57 | 1 |
| May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment | 57 | 1 |
| Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D | 58 | 1 |
| Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |
